Smith & Nephew (LON:SN) Stock Price Target Cut by Jefferies Financial Group

Smith & Nephew (LON:SN) had its price target dropped by equities research analysts at Jefferies Financial Group from GBX 1,500 to GBX 1,400 in a research note issued on Thursday, Marketbeat Ratings reports. The firm presently has a “buy” rating on the stock. Jefferies Financial Group‘s price target indicates a potential upside of 20.59% from the stock’s previous close.

A number of other research analysts also recently commented on SN. Berenberg Bank lowered their target price on Smith & Nephew from GBX 1,300 to GBX 1,250 and set a “hold” rating on the stock in a research note on Friday, August 14th. Royal Bank Of Canada decreased their price target on Smith & Nephew from GBX 1,350 to GBX 1,250 and set a “sector perform” rating for the company in a research note on Thursday, August 6th. Shore Capital Group restated a “buy” rating and set a GBX 1,000 price target on shares of Smith & Nephew in a report on Tuesday, July 21st. Citigroup lowered Smith & Nephew to a “buy” rating in a research note on Friday, July 10th. Finally, JPMorgan Chase & Co. cut their price target on Smith & Nephew from GBX 1,438 to GBX 1,290 and set a “neutral” rating for the company in a report on Thursday, August 6th. Three research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of GBX 1,242.50.

Smith & Nephew Trading Down 1.9%

LON SN opened at GBX 1,161 on Thursday. The company has a debt-to-equity ratio of 73.07, a current ratio of 2.14 and a quick ratio of 0.84. The stock has a fifty day moving average of GBX 1,058.49 and a two-hundred day moving average of GBX 1,151.65. The firm has a market capitalization of £12.73 billion, a P/E ratio of 41.80, a PEG ratio of 0.46 and a beta of 0.69.

Smith & Nephew Company Profile

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.